132 related articles for article (PubMed ID: 38126101)
1. A dermatological perspective: eosinophilic eruption of hematoproliferative disease as a clinical and histological dilemma.
Orlic T; Minic S; Manojlovic-Gacic E; Zivanovic D; Kapetanovic I
Acta Dermatovenerol Alp Pannonica Adriat; 2023 Dec; 32(4):183-186. PubMed ID: 38126101
[TBL] [Abstract][Full Text] [Related]
2. Eosinophilic dermatosis in a patient with chronic lymphocytic leukemia: a rare case report.
Gardikioti A; Venou TM; Mainou M; Nikolaidou C; Klonizakis P; Vetsiou E; Psarras K; Vlachaki E
Acta Dermatovenerol Alp Pannonica Adriat; 2021 Dec; 30(4):161-164. PubMed ID: 34929993
[TBL] [Abstract][Full Text] [Related]
3. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
5. Eosinophilic folliculitis, eosinophilic dermatosis of hematologic malignancy and acneiform follicular mucinosis: Two case reports and a review of the literature highlighting the spectrum of histopathology.
Bailey CAR; Laurain DA; Sheinbein DM; Jones HA; Compton LA; Rosman IS
J Cutan Pathol; 2021 Mar; 48(3):439-450. PubMed ID: 33617128
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab.
Arampatzis S; Giannakoulas N; Liakopoulos V; Eleftheriadis T; Kourti P; Karasavvidou F; Matsouka P; Stefanidis I
BMC Nephrol; 2011 Jul; 12():33. PubMed ID: 21729272
[TBL] [Abstract][Full Text] [Related]
7. Insect-bite-like reaction in patients with chronic lymphocytic leukemia: a study from the Israeli Chronic Lymphocytic Leukemia Study Group.
Bairey O; Goldschmidt N; Ruchlemer R; Tadmor T; Rahimi-Levene N; Yuklea M; Shvidel L; Berrebi A; Polliack A; Herishanu Y;
Eur J Haematol; 2012 Dec; 89(6):491-6. PubMed ID: 23033927
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous Masses as an Unusual Manifestation of Relapse in a Case of Atypical Chronic Lymphocytic Leukemia with Prolymphocytoid Transformation and Complex Karyotype: A Diagnostic Dilemma and Treatment Challenge.
Aldapt MB; Soliman D; Szabados L; Sharaf Eldean MZ; Shwaylia HM; Abdulla MAJ; Yassin MA
Am J Case Rep; 2020 May; 21():e920411. PubMed ID: 32388531
[TBL] [Abstract][Full Text] [Related]
9. Flame figures associated with eosinophilic dermatosis of hematologic malignancy: is it possible to distinguish the condition from eosinophilic cellulitis in patients with hematoproliferative disease?
Qiao J; Sun CE; Zhu W; Zhu D; Fang H
Int J Clin Exp Pathol; 2013; 6(8):1683-7. PubMed ID: 23923089
[TBL] [Abstract][Full Text] [Related]
10. A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.
Izutsu K; Kinoshita T; Takizawa J; Fukuhara S; Yamamoto G; Ohashi Y; Suzumiya J; Tobinai K
Jpn J Clin Oncol; 2021 Mar; 51(3):408-415. PubMed ID: 33244584
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM
Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678
[TBL] [Abstract][Full Text] [Related]
12. Recurrent skin eruption in patient with chronic lymphocytic leukemia and lymphocytic infiltrates of the dermis resembling Sweet's syndrome.
Wawrzycki B; Chodorowska G; Pietrzak A; Krasowska DW; Wąsik S; Dybiec E; Lotti T; Hercegova J
G Ital Dermatol Venereol; 2011 Dec; 146(6):487-92. PubMed ID: 22095180
[TBL] [Abstract][Full Text] [Related]
13. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
14. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
[TBL] [Abstract][Full Text] [Related]
15. Paraneoplastic Eosinophilic Dermatosis in a Case of Chronic Lymphocytic Leukemia.
Rajput CD; Nikam BP; Malani SS
Indian Dermatol Online J; 2019; 10(1):61-63. PubMed ID: 30775302
[TBL] [Abstract][Full Text] [Related]
16. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
[TBL] [Abstract][Full Text] [Related]
17. T-cell papulosis associated with B-cell malignancy: a distinctive clinicopathologic entity.
Visseaux L; Durlach A; Barete S; Beylot-Barry M; Bonnet N; Chassine A; Franck N; Herve G; Leclec'h C; Machet L; Ingen-Housz-Oro S; Petrella T; Vergier B; Ortonne N; Grange F
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1469-1475. PubMed ID: 29356170
[TBL] [Abstract][Full Text] [Related]
18. Leukemia cutis in B-cell chronic lymphocytic leukemia presenting as an episodic papulovesicular eruption.
Rosman IS; Nunley KS; Lu D
Dermatol Online J; 2011 Sep; 17(9):7. PubMed ID: 21971272
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib-Induced Skin Rash.
Kirar S; Gogia A; Gupta R; Mallick S
Turk J Haematol; 2021 Feb; 38(1):81-83. PubMed ID: 33053966
[No Abstract] [Full Text] [Related]
20. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Jain N; Thompson P; Burger J; Ferrajoli A; Takahashi K; Estrov Z; Borthakur G; Bose P; Kadia T; Pemmaraju N; Sasaki K; Konopleva M; Jabbour E; Garg N; Wang X; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang S; Lopez W; Ayala A; Plunkett W; Gandhi V; Kantarjian H; O'Brien S; Keating M; Wierda WG
Leukemia; 2021 Dec; 35(12):3421-3429. PubMed ID: 34007049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
